DFX Intelligence
Affini-T Therapeutics, Inc.
Venture-backed company · Stage unknown· Watertown, MA
As of · the latest observation of this company; each round carries its own date
Form D industry: Biotechnology
As of · the latest observation of this company; each round carries its own date
2 additional officers and directors
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
- 5 directorsboard
5 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Drawing the relationship network…
Facts
Financing history
1 round
- Jul 31, 2024Form D equity offering · $17.6M (form d sold) · 65 investorsFact Form D · “Affini-T Therapeutics, Inc. filed Form D: $17,617,952 sold of $17,617,952, Biotechnology”
Investors on record
1 edge
- Vida Ventures Management board only, Arjun Goyal (strongly supported) Inference sec.gov
Ownership and outcomesHow these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.
none on record
Outcome stated by investors
No firm portfolio page lists this company, so no outcome is stated.
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.
Credit relationshipsHow a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.
none on record
No lender position matched to this company.
People
3 officers, 5 directors
- Joseph Knowles Executive Officer/Director sec.gov
- Kathy Bergsteinsson Executive Officer sec.gov
- Kathy Yi Executive Officer sec.gov
- Lucio Iannone Director Fact
- Jill Desimone Director Fact
Show all 6 officers and directors
- Joseph Knowles Executive Officer/Director sec.gov
- Kathy Bergsteinsson Executive Officer sec.gov
- Kathy Yi Executive Officer sec.gov
- Lucio Iannone Director Fact
- Jill Desimone Director Fact
- Daniel Faga Director Fact
Timeline
1 event
- Oct 15, 2024Affini-T Therapeutics, Inc. filed Form D: $17,617,952 sold of $17,617,952, BiotechnologyForm D filed Fact Form D
Evidence
15 observations
Every observation on this company
- Entity type: Corporation Oct 15, 2024 Fact Form D
- Form D industry group: Biotechnology Oct 15, 2024 Fact Form D
- Amendment: false Oct 15, 2024 Fact Form D
- Revenue range (Form D): Decline to Disclose Oct 15, 2024 Fact Form D
- Incorporated: withinFiveYears Oct 15, 2024 Fact Form D
- Jurisdiction: Delaware Oct 15, 2024 Fact Form D
- Amount sold (Form D): $17.6M Oct 15, 2024 Fact Form D
- Offering amount (Form D): $17.6M Oct 15, 2024 Fact Form D
- Exemptions: 06b Oct 15, 2024 Fact Form D
- First sale: 2024-07-31 Oct 15, 2024 Fact Form D
- Investors (Form D): 65 Oct 15, 2024 Fact Form D
- Minimum investment (Form D): 0 Oct 15, 2024 Fact Form D
- Securities offered: Equity, option Oct 15, 2024 Fact Form D
- Office address: Oct 15, 2024 Fact Form D
- Year of incorporation: 2020 Oct 15, 2024 Fact Form D
Record history
1 dated event on the change ledger, latest event first
- Form D filed2024-10-15source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.